Skip to content

Clinical study on the prognostic effect of metoprolol combined with amiodarone on persistent atrial fibrillation after radiofrequency ablation

Clinical study on the prognostic effect of metoprolol combined with amiodarone on persistent atrial fibrillation after radiofrequency ablation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104276
Enrollment
Unknown
Registered
2025-06-13
Start date
2025-06-15
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent atrial fibrillation

Interventions

Experimental group:None
Control group:None

Sponsors

Affiliated Qingyuan Hospital, Guangzhou Medical University,Qingyuan People's Hospital;
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Experimental group: (1) meet the criteria for continuous diagnosis and be diagnosed in our hospital; (2) Radiofrequency ablation treatment by our hospital; (3) No history of allergy to the drugs related to this study; (4) Age 18~70 years old; (5) Cardiac function grade: NYHA classification is I.~III.; (6) simultaneous treatment of metoprolol sustained-release tablets and amiodarone tablets; 2. Control group: (1) meet the criteria for continuous diagnosis and be diagnosed in our hospital; (2) Radiofrequency ablation treatment by our hospital; (3) No history of allergy to the drugs related to this study; (4) Age 18~70 years old; (5) Cardiac function grade: NYHA classification is I.~III.; (6) Use only amiodarone tablets for treatment.

Exclusion criteria

Exclusion criteria: 1. Severe malignant tumors, hyperthyroidism, coagulation insufficiency; 2. Rheumatic valvular heart disease, pulmonary heart disease; 3. Cardiac function grade IV; 4. Liver and kidney insufficiency (aspartate aminotransferase or alanine aminotransferase= 3 times the upper limit of normal; Creatinine >3.5mg/dl or endogenous creatinine clearance <30 ml/min), electrolyte disorders; 5. Combined with bronchospasm; 6. Allergy to the drugs used in this study; 7. Heart rate less than 60 beats/min; 8. Have a new myocardial infarction; 9. Have a history of COPD; 10. Have a severe infection; 11. Thrombocytopenia (platelet <=80×10^9 /L, or with anticoagulation contraindications); 12. History of surgery in the past 3 months; 13. Pregnant women; 14. Life expectancy is less than 1 year; 15. Hospital transfer, loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Atrial fibrillation;Atrial flutter;Atrial tachycardia;

Countries

China

Contacts

Public ContactXiaojian Liu

Qingyuan Hospital Affiliated to Guangzhou Medical University

9.20@163.com+86 13926689204

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026